Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 458

1.

Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis.

Barratt G, Legrand P.

Curr Opin Infect Dis. 2005 Dec;18(6):527-30. Review.

PMID:
16258327
2.

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.

Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.

Clin Infect Dis. 2004 Feb 1;38(3):377-83. Epub 2004 Jan 13.

PMID:
14727208
3.

Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.

Minodier P, Retornaz K, Horelt A, Garnier JM.

Fundam Clin Pharmacol. 2003 Apr;17(2):183-8. Review.

PMID:
12667228
4.

Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.

Murray HW.

Expert Rev Anti Infect Ther. 2004 Apr;2(2):279-92. Review. Erratum in: Expert Rev Anti Infect Ther. 2004 Jun;2(3):462.

PMID:
15482193
5.

Overview of the lipid formulations of amphotericin B.

Dupont B.

J Antimicrob Chemother. 2002 Feb;49 Suppl 1:31-6. Review.

PMID:
11801578
6.

Amphotericin B lipid complex: in visceral leishmaniasis.

Goldsmith DR, Perry CM.

Drugs. 2004;64(17):1905-11; discussion 1912-3. Review.

PMID:
15329037
8.

Advances in the treatment of leishmaniasis.

Sundar S, Rai M.

Curr Opin Infect Dis. 2002 Dec;15(6):593-8. Review.

PMID:
12821836
9.

What is the current and future status of conventional amphotericin B?

Kleinberg M.

Int J Antimicrob Agents. 2006 Jun;27 Suppl 1:12-6. Epub 2006 May 16. Review.

PMID:
16707251
10.

Lipid-based formulations of amphotericin B.

Veerareddy PR, Vobalaboina V.

Drugs Today (Barc). 2004 Feb;40(2):133-45. Review.

PMID:
15045035
11.

Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis.

Wortmann GW, Fraser SL, Aronson NE, Davis C, Miller RS, Jackson JD, Oster CN.

Clin Infect Dis. 1998 Apr;26(4):1006-7. No abstract available.

PMID:
9564500
12.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
13.

Current treatment approaches to leishmaniasis.

Berman J.

Curr Opin Infect Dis. 2003 Oct;16(5):397-401. Review.

PMID:
14501991
14.

Drug regimens for visceral leishmaniasis in Mediterranean countries.

Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, CaƱavate C, Dujardin JC.

Trop Med Int Health. 2008 Oct;13(10):1272-6. doi: 10.1111/j.1365-3156.2008.02144.x. Epub 2008 Aug 24.

15.

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.

Gangneux JP, Sulahian A, Garin YJ, Derouin F.

Trans R Soc Trop Med Hyg. 1996 Sep-Oct;90(5):574-7.

PMID:
8944278
16.

Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.

Amato VS, Tuon FF, Campos A, Bacha HA, Nicodemo AC, Amato Neto V, Shikanai-Yasuda MA.

Clin Infect Dis. 2007 Jan 15;44(2):311-2. No abstract available.

PMID:
17173238
17.

Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients.

Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, Floeter-Winter LM, Neto VA, Shikanai-Yasuda MA.

Acta Trop. 2004 Oct;92(2):127-32.

PMID:
15350864
18.

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

Sundar S, Goyal AK, More DK, Singh MK, Murray HW.

Ann Trop Med Parasitol. 1998 Oct;92(7):755-64.

PMID:
9924533
19.
20.

Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.

Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M.

Clin Infect Dis. 2006 Mar 1;42(5):608-13. Epub 2006 Jan 20.

PMID:
16447104

Supplemental Content

Support Center